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Background: The prevalence of hypertension is increasing particularly among obese
children and adolescents. Obese children and adolescents with hypertension are likely to
remain hypertensive as they reach adulthood and hypertension is linked to an increased
risk for cardiovascular disease. Twenty-four-hour ambulatory blood pressure monitoring
(ABPM) has become one of the most important tools in diagnosing hypertension in
children and adolescents and circadian patterns of blood pressure may be important
disease-risk predictors.
Methods: A retrospective chart review was conducted in patients aged 6–21 years who
underwent 24-h ABPM at Kentucky Children’s Hospital (KCH) from August 2012 through
June 2017. Exclusion criteria included conditions that could affect blood pressure
including chronic kidney disease and other renal abnormalities, congenital heart disease,
cancer, and thyroid disease. Subjects were categorized by body mass index into normal
(below 85th percentile), overweight (85th−95th percentile), stage I obesity (95th−119th
percentile), stage II obesity (120th−139th) and stage III obesity (>140th). Non-dipping
was defined as a nocturnal BP reduction of <10%.
Results: Two hundred and sixty-three patients (156 male patients) were included in the
analysis, of whom 70 were normal weight, 33 overweight, 55 stage I obesity, 53 stage
II, and 52 stage III obesity. Although there was no significant difference between normal
weight and obese groups for prevalence of hypertension, there was a greater prevalence
of SBP non-dipping in obese patients as BMI increased (p = 0.008). Furthermore,
non-dippers had a significantly elevated LVMI as well as abnormal lab values for uric
acid, blood lipid panel, creatinine, and TSH (p < 0.05).
Conclusions: These findings demonstrate that obese children and adolescents
constitute a large proportion of hypertensive children and adolescents and the severity
of pediatric obesity is associated with nocturnal BP non-dipping. Additionally, obesity
in children is linked to several cardiovascular risk factors including left ventricular
hypertrophy, dyslipidemia, and elevated uric acid levels. Further studies utilizing ABPM
measures on risk stratification in this very high-risk population are warranted.
Keywords: blood pressure, pediatric, obesity, cardiovascular risk, nocturnal dipping, left ventricular hypertrophy
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INTRODUCTION
Childhood obesity and associated cardiometabolic disease
including hypertension are increasing at an alarming rate
worldwide. Currently 18.5% of children and adolescents (∼13.7
million) are obese in the United States with rates of obesity
increasing in all age groups in the pediatric population (1). A
recent systematic review and meta-analysis examining the global
prevalence of childhood hypertension reports that hypertension
has increased from 1994 to 2018 with a pooled estimate of 4%
and is associated with high body mass index (2). According to the
National Health and Nutrition Examination Survey (NHANES)
the prevalence of elevated blood pressure in children between the
ages of 8–17 is reported to be 19% in boys and 13% in girls which
is a 24% increase from 1988 to 1994 (3). This is an alarming
report since pediatric blood pressure is a strong predictor of
adult hypertension (4). Similarly, childhood obesity has been
shown to project into adulthood (5, 6) leading to increased
risk for cardiovascular disease such as heart failure, stroke, and
myocardial infarction.
Pediatric hypertension has been associated with target-
organ damage including left ventricular hypertrophy (LVH) (7),
impaired cognition (8), and subclinical markers of cardiovascular
disease such as increased carotid intima thickness (9). Risk
factors for pediatric hypertension have not clearly been defined;
however, children with obesity are at increased risk (10) as well as
children with chronic kidney disease (11).
Ambulatory blood pressure monitoring (ABPM) provides a
comprehensive assessment of blood pressure over a 24-h period
and is recommended by the 2017 AAP CPG for the confirmation
of the diagnosis of hypertension. Additionally, ABPM is
recommended for the evaluation for masked hypertension,
suspected white-coat hypertension, risk for hypertensive target
organ damage, evaluation of hypertension in children with
obstructive sleep apnea syndrome, secondary hypertension,
chronic kidney disease or structural renal abnormalities, type 1
and type 2 diabetes, history of solid organ transplant, history
of pre-maturity and evaluation of non-dipping status, as well
as patients with history of aortic coarctation repair, in addition
to assessment and monitoring of treatment effectiveness of
antihypertensive medications (12). Strojny et al. assessed ABPM
as a diagnostic tool in hypertension in children as well as
prevalence of metabolic syndrome and found altered circadian
blood pressure patterns in 50% of obese patients (13).
Traditional BMI categories of normal weight vs. overweight
and obesity have been widely accepted as screening tools
for cardiometabolic risk because of their simplicity, cost-
effectiveness, and strong correlation with cardiac magnetic
resonance imaging (CMR). Within the previous two decades,
there has a been a significant increase in the prevalence of
extreme obesity as defined by a BMI of at least 99th percentile
on the CDC growth charts (14). Due to this increased adiposity,
Flegal et al. have developed further classification schemes for
extreme obesity by using modeling to derive an extended growth
curve percentile for children. The additional sub-categories
include class I (BMI is 95th to 120% of the 95th percentile),
class II (BMI 120–140% of the 95th percentile), and class III
[BMI>140% of the 95th percentile (15)]. In 2013, The American
Heart Association and the Endocrine Society Guidelines on
Childhood Obesity endorsed the definition of extreme obesity
in children 2 years of age and older as a BMI > 120% of
the 95th percentile or an absolute BMI > 35 kg/m2 (16).
Cardiovascular risk factors associated with pediatric obesity
include dyslipidemia, hypertension, insulin resistance, and the
metabolic syndrome, as well as other non-traditional risk factors
including increased levels of homocysteine, uric acid, and C-
reactive protein (14).
Left ventricular hypertrophy (LVH) is readily assessed by
echocardiography and is a form of target organ damage (17).
The AAP CPG defines LVH as LV mass >51 g/m2.7 for children
older than 8 years of age and recommends echocardiograms
be obtained when the initiation of antihypertensive medication
is considered to assess target organ damage (18). ABPM has
been shown to correlate with target organ damage such as left
ventricular hypertrophy in adults (19). LVH has been shown to
be related to obesity independent of blood pressure changes (20).
The aim of this study was to evaluate relationships of elevated
blood pressure and several established markers of cardiovascular
and metabolic disease among patients stratified according to
obesity and treated at the KCH Pediatric Nephrology Clinic.
Furthermore, this study tests the hypothesis that severity of
obesity correlates with increased cardiovascular risk including
non-dipping and left ventricular hypertrophy.
MATERIALS AND METHODS
Research and Design
This study was conducted as a retrospective chart review in
children who were referred to the KCH Pediatric Nephrology
Clinic with elevated blood pressure who underwent a first time
24-h ABPM between August 2012 through June 2017. This study
evaluates the relationship between blood pressure and several
established markers of cardiovascular and metabolic disease
based on severity of obesity. This study was approved by the
University of Kentucky Institutional Review Board.
Selection Criteria and Outcomes Reported
Patients were selected via the electronic medical record to
identify those patients who underwent a 24-h ABPM from
KCH during the study timeframe. Exclusion criteria included
conditions that could affect blood pressure including chronic
kidney disease, congenital heart disease, cancer patients, patients
with ADHD on stimulant medication, and thyroid disease.
Data collected included demographic (date of birth, gender,
ethnicity/race) and diagnostic evaluation (age at presentation,
ABPM report, diagnostic testing including echocardiogram, and
laboratory findings) from the electronic medical record.
All ABPMs were performed using Spacelabs (Issaquah,
WA) 90217 monitor or an Oscar 2 ABPM Monitor by
SunTech Medical which are validated by the Association for the
Advancement of Medical Instrumentation for use in children.
The monitor was placed by trained nursing staff at the time of
clinic visit with an appropriate cuff size. Readings were taken
every 30min while awake and every 60min while asleep. Patients
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were asked to record sleep and wake times during the 24-h period
and were instructed to mail this information along with the
device back to our office for interpretation of results. Patients
were advised to follow routine daily activities but avoid vigorous
exercise and to relax the arm during inflation and deflation
of the cuff. The adequacy of the study was determined by the
interpreting physician at the time of ABPM evaluation according
to the Ambulatory Blood Pressure Monitoring in Children and
Adolescents: Recommendations for Standard Assessment and
included at least 65% successful readings (21). Patients were
categorized according to the ABPM definition as normal, pre-
hypertension, ambulatory hypertension, or severe hypertension
(21). Non-dipping was defined as a nocturnal BP reduction of
<10% from mean systolic and diastolic awake BP.
Patients’ gender, age, height, and weight were measured at the
clinic visit. BMI was calculated and plotted on CDC growth chart
for gender and age. Data were available for BMI determination
in all subjects. Subjects were categorized by body mass index
into normal (below 85th percentile), overweight (85th−95th
percentile), stage I obesity (95th−119th percentile), stage II
obesity (120th−139th) and stage III obesity (>140th) based on
the updated CDC growth charts.
Laboratory assessment including renal function panel,
blood lipid panel (total cholesterol, HDL, LDL, triglycerides),
hemoglobin A1c, uric acid, and renin-aldosterone-cortisol, and
thyroid levels were obtained retrospectively. Cardiac imaging via
echocardiogram to determine evidence of target organ damage
was reported as well. Left ventricular hypertrophy (LVH) was
defined as LV mass indexed to height in meters to the 2.7 power
that is greater than the 95th percentile for age and sex (22).
Statistical Analysis
Bivariate statistical analyses were performed via IBM SPSS
Statistics version 25. (IBM Corp., Armonk, NY, USA) with
significance set at an alpha level <0.05. Modeling was performed
in SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
Continuous variables including lab values such as blood lipid
panel, hemoglobin A1c, uric acid, thyroid, renin-aldosterone-
cortisol, and LVMI were analyzed using ANOVA utilizing a
post-hoc pairwise comparison with a Bonferroni correction and
independent samples t-test. Categorical and ordinal variables
including gender, BMI stage, blood Pressure stage were analyzed
using Pearson’s chi-square while non-dipping prevalence were
analyzed through Somer’s D-test. Additionally, a generalized
linear multivariate model was used to examine the interaction
of BMI stage and gender on LVMI with significance set at an
alpha level <0.05.
RESULTS
A total of 496 completed ABPMs were identified during the study
period August 2012 through June 2017; 100 were excluded due
to an underlying chronic condition as described in the methods
section, an additional 46 of these were repeat ABPMs, and 87
were excluded due to inadequate sample collection (completed
readings below 65%). Of those remaining, 263 ABPMs and
associated patient data were included in the analysis, of whom
TABLE 1 | Patient characteristics.
Normal Overweight OB Class I OB Class II OB Class III
N % 70 (27) 33 (13) 55 (20) 53 (20) 52 (20)
Age (yr), Mean
± SD
14.1 ± 2.9 14.5 ± 2.5 14.1 ± 2.90 13.5 ± 2.55 13.3 ± 2.8
Gender
Male, n (%) 35 (50) 19 (58) 28 (51) 39 (74) 37 (72)








10 (15) 6 (18) 2 (3) 5 (10) 11 (22)
Other, n (%) 2 (2) 0 (0) 0 (0) 0 (0) 1
Unreported, n
(%)
0 (0) 0 (0) 0 (0) 1 3 (6.5)
BMI (kg/m2),
Mean ± SD
20.2 ± 3.1 25.3 ± 2.4 29.4 ± 3.11 33.6 ± 3.64 39.8 ± 5.6
70 (27%) were normal weight, 33 (13%) were overweight, 55
(20%) were class I obesity, 53 (20%) were class II obesity, and
52 (20%) were class III obesity. The mean age was 13.9 ± 0.17
with 98% patients (n= 259) 18 years or younger, 40% are female
and there were no significant differences among gender and age
in each obesity class. Demographics including age, gender, race,
and mean BMI are found in Table 1.
ABPM findings including 24-h systolic blood pressure and
diastolic blood pressure, as well as mean day and night SBP
and DBP according to obesity class are reported in Table 2
with the number of successful readings during sleep in each
category is as follows: normal weight:9.64 ± 0.469, overweight:
8.25 ± 0.651, stage I obesity: 8.95 ±0.492, stage II: 8.44 ±
0.371, stage III: 8.32 ± 0.582 (p = 0.161). The different stages
of hypertension as defined by ABPM which takes into account
the mean ambulatory systolic blood pressure and load were
not significantly different among obesity classes (p = 0.161,
Figure 1). Prevalence of non-dipping (defined as nocturnal BP
reduction of <10%) significantly increased as severity of obesity
increased for systolic blood pressure (n = 8 in overweight; n =
21 in stage I obesity, n= 24 in stage II obesity, n= 27 in stage III
obesity, p= 0.008; Figure 2); however, no differences were noted
in nocturnal diastolic blood pressure dip (p= 0.15, Table 2).
Of the patients who underwent ABPM measurement and
included in analysis, 234 patients had a renal function panel
measured and 178 had lipid panel measured. Total cholesterol
was significantly elevated as severity of obesity increased (p <
0.001) in addition to significant increases in serum triglyceride
(p < 0.001, Figure 3). There was an inverse relationship between
HDL and severity of obesity (p < 0.001). Levels of uric acid
were found to be significantly elevated with stage II and III
obesity (p < 0.001). HgbA1c was measured in 109 patients
and found to be elevated in overweight and obese groups
compared to normal weight groups (p < 0.05, Figure 4). No
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24-h SBP 131.1 ± 1.33 132.13 ± 2.46 134.30 ± 2.04 134.37 ± 1.72 131.55 ±1.51 0.503
24-h DBP 75.03 ± 1.22 72.72 ±1.12 72.76 ±1.17 72.28 ± 0.99 70.70 ± 1.17 0.0951
Day SBP 134.64 ± 1.35 134.78 ± 2.05 137.02 ±1.73 137.02 ±1.73 135.42 ±1.84 0.703
Day DBP 78.44 ±1.14 75.88 ±1.16 76.31 ±1.24 75.28 ±1.06 73.0 ±1.kh 0.015
Night SBP 120.14 ±1.66 119.76 ± 2.45 119.89 ± 1.62 123.45 ± 2.16 121.96 ± 1.54 0.565
Night DBP 64.78 ± 1.31 61.15 ± 1.27 61.12 ± 0.96 62.19 ± 1.20 60.71 ± 0.88 0.056
Nocturnal SBP non-dipping, n (%) 31 (44.3%) 8 (24.2%) 21 (38.2%) 24 (45.3%) 27 (51.9%) 0.008
Nocturnal DBP non-dipping, n (%) 15 (21.4%) 4 (12.1%) 6 (10.9%) 9 (17%) 7 (13.7%) 0.1539
Number of sleep readings 9.64 ± 0.469 8.25 ± 0.615 8.95 ±0.492 8.44 ± 0.371 8.32 ± 0.582 0.161
Bolded value indicates a p < 0.05.
FIGURE 1 | Prevalence of hypertension in relation to stage of obesity
(n = 263) as tested by Pearson’s chi square-test.
FIGURE 2 | Prevalence of non-dipping increases with severity of obesity.
Values are presented as percentage with Somer’s D-test (p = 0.008,
Somer’s D-test).
statistical differences were found in measurements of renal
function, vitamin D levels, or the hormones renin, aldosterone,
and cortisol across classes of obesity (Supplementary Figure 1).
FIGURE 3 | Lipid profile based on stage of obesity. Values are presented as
mean ± SEM with One-Way ANOVA-test as appropriate (#p < 0.001 for total
cholesterol, triglycerides; *p < 0.05 for HDL compared to normal
weight group).
TSH was significantly elevated in class II and III obesity
suggesting a hypothyroid phenotype (p < 0.05). Of those
patients who underwent ABPM measurement and included in
analysis, 197 patients underwent echocardiogram (117 were
male) with 6% (n = 11) diagnosed with LVH. Left ventricular
mass index assessed via echocardiogram revealed a significant
elevation with severity of obesity (normal weight: 33.95 ± 0.41;
overweight: 43.4 ± 1.07, stage I: 50.4 ± 1.77; stage II: 52.64
± 1.79; stage III: 57.9 ± 1.8, p < 0.001, Figure 5A). Further
examination reveals that the effect of LVMI is correlated with
obesity stage (Figure 5A) but not with blood pressure level
(one-way ANOVA, p = 0.709) or non-dipping (Chi square-
test, p = 0.721). When we further analyzed the difference in
LVMI, we found an interaction between LVMI and gender.
Although normal weight girls have a lower LVMI than normal
weight boys, LVMI has higher values for girls in stage III
obesity than boys (49.89 ± 4.92 vs. 45.09 ± 2.92, Figure 5B,
p= 0.030).
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FIGURE 4 | Serum markers of glucose metabolism and cardiovascular risk. (A) HgbA1C and (B) Uric Acid Values are presented as mean ± SEM with One-Way
ANOVA-test as appropriate (#p < 0.001 for uric acid; *p < 0.05 for HgbA1C compared to normal weight group).
FIGURE 5 | (A) LVMI increases with stage of obesity. Values are presented as mean ± SEM with One-Way ANOVA-test with Bonferroni post-hoc analysis ap < 0.001
compared to normal weight; bp < 0.001 compared to overweight group. (B) Gender and LVMI. ap < 0.001 compared to normal weight for boys. bp < 0.001
compared to normal weight for girls; cp < 0.05 compared to overweight for girls; dp < 0.05 compared to stage I obesity for girls; ep < 0.05 compared to stage II
obesity for girls. Interaction between gender and obesity rank: p < 0.05.
DISCUSSION
This study examined several hemodynamic and biochemical
markers of cardiovascular risk with respect to obesity class and
demonstrated that the prevalence of non-dipping during 24h
BP monitoring was more prevalent with increasing severity
of obesity. Furthermore, several cardiovascular risk markers
including total cholesterol, triglycerides, uric acid levels, and
LVMI were significantly associated with severity of obesity. We
found a potentially important trend of increased prevalence of
non-dipping and greater left ventricular mass in the most severe
obesity classes.
Nocturnal dip is defined as a nocturnal blood pressure
reduction of <10% from mean systolic and diastolic awake BP
during the nighttime. The relationships between non-dipping
status and target organ damage and cardiovascular morbidity
is well-established in adults. Non-dipping in the pediatric
population has been less studied but reveals associations with
target organ damage such as LVH in diabetic populations (23)
and a lower GFR in children with chronic kidney disease (24).
Framme et al. examined dipping status and obesity in children
and found a significant impact only in females (25) whereas our
findings found a relationship in both genders as well as reported
by others (26). Our findings reveal of prevalence of 45% non-
dipping among obese patients compared to 34% by Macumber’s
study and 40% by Westerstahl’s study (27). Furthermore, we
report a positive association between severity of obesity and
non-dipping status. The relationship between nocturnal dipping
and obstructive sleep apnea in children remains mixed (28,
29); however; it is likely that our study included patients with
undiagnosed sleep apnea.
Similar to our findings, the ERICA study from Brazil
reports an increase in prevalence of several cardiovascular
risk factors including total cholesterol, LDL cholesterol,
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low HDL levels, and HgbA1c in relation to severity of
obesity in addition to blood pressure (30). Skinner at al.
demonstrated that children aged 3–19 years of age with class
III obesity had a >2-fold increased risk of hyperglycemia and
hypertension (31). Data from NHANES of 20,905 youth aged
6–19 years revealed that odds for elevated blood pressure,
hypercholesterolemia, and fasting hyperglycemia progressively
doubled with each stage of obesity (32). Another study of
severely obese adolescents enrolled at a National Obesity Center
in Sweden examined the relationship between insulin-glucose
metabolism, nocturnal blood pressure dipping and cardiac left
ventricular mass and found that non-dipping was common
and negatively associated with measures of insulin metabolism
including Homeostatic Model Assessment of Insulin Resistance
(HOMA) index and fasting insulin (27). They did not find
associations between dipping status and HgA1c or LVMI.
Since the HOMA index primarily reflects insulin levels, this
suggests that high insulin levels could be important in the
pathogenesis of non-dipping and should be monitored closely.
Others have found that impaired glucose tolerance triples
the risk of non-dipping among normotensive adults without
diabetes (33).
Published findings in adult populations have demonstrated
an association between serum uric acid and increased CVD
mortality independent of traditional risk factors (34). A
prospective 1 year study of 53 children and adolescents with
hypertension found relationships between elevated uric acid and
cardiovascular risk factors including adiposity, low HDL levels,
CRP, and left ventricular hypertrophy; however, there were was
no association between uric acid and hypertension (35). A more
recent study with 333 obese youth aged 5–18 years examined the
relationship between uric acid, ABPM, and other cardiometabolic
risk factors and found a positive association between uric acid
levels and blood pressure, insulin, and triglyceride levels (36).
Our findings demonstrate a positive relationship between uric
acid and severity of obesity.
The level and duration of BP elevation that result in target
organ damage in children and adolescents remain poorly defined;
however, LVH has been noted in this population with even mild
blood pressure elevation and is probably the most well-studied
marker of target organ damage because of the wide availability
of echocardiography. In hypertensive children, the prevalence
of LVMI ranges from 4.8 to 50% and can be even higher in
children on dialysis (37–39). Daniels et al. reported that 47% of
pediatric patients with hypertension also had a LVMI greater than
the 95th percentile for LVMI in normal children and 8% had a
LVMI >51 g/m2.7 (17). In a European study, it was found that
pediatric patients with a new diagnosis of hypertension also had
a 41% prevalence of LVH with 13.2% exhibiting a LVMI greater
than the adult cutoff point (Litwin et al.). LVMI has been linked
with ambulatory blood pressure parameters including nighttime
SBP, 24 h blood pressure, and pulse pressure (40, 41). Similar to
our findings, Ramaswamy et al. report a relationship between
obesity and elevated LVMI independent of blood pressure in
children who underwent 24 h blood pressure monitoring (42).
In a different study that included children with secondary forms
of hypertension, relationships were found between LVMI and
elevated BMI and boys had a significantly higher LVMI than girls
(43). However, this study did not examine whether an interaction
existed between obesity stage and gender and it included more
severe stages of hypertension due to secondary causes including
chronic kidney disease and renovascular disease. Interestingly,
our data is similar to these findings in normal weight individuals;
however, we report significant elevations in LVMI in girls with
more severe obesity. Results from the CKiD (chronic kidney
disease cohort in children) have reported a four-fold odds of
LVH among girls compared to boys (44). Additionally, studies
in young adults have reported that women with hypertension
were more likely to develop LVH than men when adjusting for
ambulatory BP and other CVD risk factors (45). We note that
our findings of differences between girls and boys in relation to
LVMI and obesity is an interesting finding and warrants further
studies with larger sample sizes.
Several studies have demonstrated that childhood
cardiovascular risk factors carry forward into adulthood. A
meta-analysis that examined the association between childhood
obesity and cardiovascular risk in adulthood found a significant
and positive association in regard to adult systolic blood
pressure, diastolic blood pressure, triglycerides, and negatively
associated with adult HDL (46). Furthermore, the Princeton
Follow-up study has shown that pediatric hypertriglyceridemia
can predict cardiovascular disease events in the fourth to fifth
decade of life (47). A recent study utilizing CVD prediction
algorithms from clinical data including serum lipids, systolic
blood pressure, diabetes status, and BMI demonstrated that
adolescents with severe obesity have a significant risk of having
a cardiovascular event before the age of 50; however, after
undergoing bariatric surgery, the predicted risk of CVD events
was significantly reduced (48). Extrapolating these results into
our own findings suggests that with severity of obesity, the
likelihood of a cardiovascular event in adulthood is increased.
Our study has several limitations including that it is a single
center retrospective experience and a cross-sectional design.
Since this study is cross-sectional and included a single time
point per study participant as a retrospective study we cannot
infer causality between different variables examined; rather
these relationships can guide additional prospective studies. In
addition, we did not collect parameters related to sodium intake
or physical activity patterns, which could affect blood pressure
findings. All of our patients were referred to our clinic for
hypertension evaluation, which may reduce the generalizability
to the pediatric population. An additional factor is the tolerability
to wearing the 24 h blood pressure monitor as it has been
reported that obese adolescents have less successful readings
and are thus more intolerant to ABPM (49). This could have
affected our results since 87 subjects (33% of the overall sample)
who underwent the ABPM-test were excluded due to inadequate
readings and this could have influenced the findings on nocturnal
dip and cardiovascular risk factors. An additional limitation of
this study is that we did not account for sleep quality through
sleep studies within these patients. Despite these limitations, we
feel that this study adds significant findings to the literature
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regarding pediatric hypertension and cardiovascular risk based
on severity of obesity as a way to stratify risk.
CONCLUSIONS
Pediatric obesity is a major health concern and obese children
are at a high risk of early cardiovascular disease. Recent strategies
to stratify severity of obesity may provide opportunity to
identify patients at highest risk. Our investigations of several
hemodynamic and biochemical markers of cardiovascular risk
with respect to Obesity Class provided the following insights: the
frequency of systolic or diastolic hypertension was not different
among obesity severity, but the prevalence of non-dipping during
24h BP monitoring was more prevalent with severity of obesity.
Several well-recognizedmarkers of cardiovascular risk are related
to severity of obesity. Blood lipid panels demonstrated elevation
in total cholesterol with a reduction in HDL, and elevation
in triglycerides in relation to severity of obesity. LVMI was
significantly associated with severity of obesity and this was
found to be more prominent in girls than boys. Our data suggests
that there may be a sex-specific target organ response and that
obesity class may help to identify the most at-risk children at
the earliest times. We found a potentially important trend of
increased prevalence of non-dipping and greater LV mass in
the most severe stages of obesity. Our studies support the use
of ABPM in the evaluation of pediatric hypertension as well
as the need to examine additional cardiovascular risk factors
at the time of evaluation. Further studies to develop easily
implemented and cost-effective risk stratification methods are
clearly warranted as are studies to define relationships among
blood pressure variables and cardiac structure and function in
high-risk obese children.
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